Contact

Category: Non classé

OGD2 Pharma to attend BIO International Convention 2026 in San Diego

OGD2 Pharma is pleased to announce its participation in BIO International Convention 2026, to be held in San Diego, California. We will be engaging in partnering meetings to discuss strategic collaborations and to present updates on our precision immunotherapy platform targeting OAcGD2. We look forward to connecting with potential clinical and commercial partners to advance […]

Professor Alice Yu joins the OGD2 Pharma Scientific Advisory Board

OGD2 Pharma is proud to welcome Professor Alice Yu to our Scientific Advisory Board. A world-renowned paediatric oncologist, Professor Yu is recognised for her foundational contributions to cancer immunotherapy, including pioneering work that led to the FDA approval of the first anti-GD2 antibody therapy for neuroblastoma. Her scientific expertise in GD2 and OAcGD2 biology, combined […]

Rare Pediatric Disease Designation to OGD201 by the FDA

OGD2 Pharma is proud to announce that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to OGD201, our lead anti-OAcGD2 immunotherapy candidate for high-risk neuroblastoma. This designation recognises the serious unmet need in this devastating childhood cancer and provides the important incentive for Priority Review Voucher eligibility upon potential […]

OGD2 Pharma establishes Medical Advisory Board

OGD2 Pharma is pleased to announce the establishment of its Medical Advisory Board (MAB) to support the clinical development of OGD201, our lead anti-OAcGD2 immunotherapy candidate for high-risk neuroblastoma. The MAB brings together three world-leading neuroblastoma specialists, namely Professor Andy Pearson (ICR & Royal Marsden Hospital), Professor Steven DuBois (Dana-Farber/Boston Children’s Hospital), and Dr. Margaret […]

Bpifrance awards ADD Deeptech grant to advance OGD201

OGD2 Pharma has been awarded a grant by Bpifrance under the “Aide au Développement Deeptech” (ADD) programme, supporting the IND-enabling development of OGD201, our lead anti-OAcGD2 immunotherapy candidate for high-risk neuroblastoma. This non-dilutive funding will support key CMC development activities, including product cell line development and optimization of manufacturing processes – essential steps toward IND/CTA […]

Advancing Paediatric Oncology at ACCELERATE 2026

OGD2 Pharma is pleased to announce its participation in the ACCELERATE Annual Conference, taking place in Brussels from 5-6 February, 2026. The meeting is a leading forum dedicated to accelerating drug development in paediatric oncology. We will be engaging with international clinicians, regulatory specialists, and pharma partners active in the paediatric oncology space to discuss […]

Thank you for your message. We have received your request and appreciate your interest in our services. Our team will review it and get back to you as soon as possible with a response.

We look forward to speaking with you soon.

Margaret (Meg) Macy

Director, Experimental Therapeutics Program, Children's Hospital Colorado

Dr. Macy directs the Experimental Therapeutics Program at Children’s Hospital Colorado, the only early-phase paediatric oncology trial centre in the Rocky Mountain Region. She serves as institutional principal investigator for both the Pediatric Early Phase Clinical Trials Network (PEP-CTN) and the New Agents in Neuroblastoma Therapy (NANT) consortium. Her research focuses on relapsed/refractory neuroblastoma, with leadership roles across multiple COG and NANT trials including ANBL1821, ANBL2421, and a novel international biomarker platform study. She also serves as Medical Director for the Colorado Child Health Research Institute, with a particular focus on precision medicine and high-risk therapeutics.

Steve Dubois

Professor of Paediatrics, Harvard Medical School

Dr. Dubois is Director of Experimental Therapeutics at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, leading programmes to advance targeted therapies for paediatric cancers. He holds a Master of Science in Epidemiology from Harvard School of Public Health and trained in paediatric oncology at Dana-Farber/Boston Children’s Hospital. His translational research focuses on neuroblastoma and Ewing sarcoma, spanning Phase I–III clinical trials and biomarker discovery. He has served on the Children’s Oncology Group Neuroblastoma Steering Committee, ASCO Scientific Program Committee, and the FDA Paediatric Oncology Drugs Advisory Committee.

Andy Pearson

Professor of Paediatric Oncology, ICR & Royal Marsden Hospital (Retired)

Professor Pearson is a globally recognised authority in neuroblastoma with 50 years of clinical and drug development experience. He held the Cancer Research UK Chair of Paediatric Oncology at the Institute of Cancer Research and served as Divisional Medical Director at the Royal Marsden Hospital. He chaired the UKCCSG Neuroblastoma Group, the European Neuroblastoma Group, and co-founded the International Neuroblastoma Risk Group. He chairs the ACCELERATE-EMA-FDA Paediatric Strategy Forum and LifeArc’s Childhood Cancer Translational Challenge. With over 430 publications and a Lifetime Achievement Award from Advances in Neuroblastoma Research, he is among the field’s most distinguished leaders.

Alice Yu

Distinguished Chair Professor, Chang Gung Memorial Hospital & Chang Gung University, Taiwan

A pioneer in cancer immunotherapy and Academician of Academia Sinica, Dr. Yu led dinutuximab from preclinical development through FDA approval in 2015, which established anti-GD2 therapy as standard of care for high-risk neuroblastoma. She is Professor Emeritus of Pediatrics at UC San Diego and Distinguished Chair Professor at Chang Gung Memorial Hospital. A long-standing member of the COG Neuroblastoma Steering Committee, she holds multiple distinguished awards including the 2025 Lifetime Achievement Award from Advances in Neuroblastoma Research and the 2020 ASCO Pediatric Oncology Award.

Brigitte Assouline

VP, Preclinical Development and IP

Expert in integrating preclinical science, regulatory strategy, and intellectual property to support clinical translation and asset differentiation.

Linkedin

Marco Alessandrini

COO & Business Development

Biotech executive with 15+ years of experience across advanced therapies, focused on strategy, operations, and strategic partnerships.

Linkedin

Jean-Marc Le Doussal

Founder & President

Immunologist, entrepreneur, and investor with a long track record of translating immunology into medicines and building science-driven biotech companies.

Linkedin